Corona Remedies Ltd vs Divis Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Corona Remedies Ltd is ₹ 1580 as of 19 Feb 10:41 . The P/E Ratio of Corona Remedies Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Divis Laboratories Ltd changed from 48.6 on March 2021 to 69.8 on March 2025 . This represents a CAGR of 7.51% over 5 years The Market Cap of Corona Remedies Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Divis Laboratories Ltd changed from ₹ 96366 crore on March 2021 to ₹ 153257 crore on March 2025 . This represents a CAGR of 9.72% over 5 years The revenue of Corona Remedies Ltd for the Dec '25 is ₹ 344.68 crore as compare to the Sep '25 revenue of ₹ 363.57 crore. This represent the decline of -5.2% The revenue of Divis Laboratories Ltd for the Dec '25 is ₹ 2692 crore as compare to the Sep '25 revenue of ₹ 2860 crore. This represent the decline of -5.87% The ebitda of Corona Remedies Ltd for the Dec '25 is ₹ 66.32 crore as compare to the Sep '25 ebitda of ₹ 80.91 crore. This represent the decline of -18.03% The ebitda of Divis Laboratories Ltd for the Dec '25 is ₹ 904 crore as compare to the Sep '25 ebitda of ₹ 1033 crore. This represent the decline of -12.49% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 41.27 crore over 7 quarters. This represents a CAGR of 20.11% The net profit of Divis Laboratories Ltd changed from ₹ 430 crore to ₹ 583 crore over 7 quarters. This represents a CAGR of 19.00% The Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 yearsThe Dividend Payout of Divis Laboratories Ltd changed from 27.16 % on March 2021 to 35.99 % on March 2025 . This represents a CAGR of 5.79% over 5 years .

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

About Divis Laboratories Ltd

Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals.
The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries.
It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports.
In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
It is among the largest pharmaceutical companies in India with a portfolio of approx.

FAQs for the comparison of Corona Remedies Ltd and Divis Laboratories Ltd

Which company has a larger market capitalization, Corona Remedies Ltd or Divis Laboratories Ltd?

Market cap of Corona Remedies Ltd is 10,550 Cr while Market cap of Divis Laboratories Ltd is 172,696 Cr

What are the key factors driving the stock performance of Corona Remedies Ltd and Divis Laboratories Ltd?

The stock performance of Corona Remedies Ltd and Divis Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Corona Remedies Ltd and Divis Laboratories Ltd?

As of May 4, 2026, the Corona Remedies Ltd stock price is INR ₹1725.0. On the other hand, Divis Laboratories Ltd stock price is INR ₹6505.35.

How do dividend payouts of Corona Remedies Ltd and Divis Laboratories Ltd compare?

To compare the dividend payouts of Corona Remedies Ltd and Divis Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.